ES2256893T3 - Secuencias antisentido antitumorales dirigidas contra componentes r1 y r2 de la reductasa ribonucleica. - Google Patents

Secuencias antisentido antitumorales dirigidas contra componentes r1 y r2 de la reductasa ribonucleica.

Info

Publication number
ES2256893T3
ES2256893T3 ES97932690T ES97932690T ES2256893T3 ES 2256893 T3 ES2256893 T3 ES 2256893T3 ES 97932690 T ES97932690 T ES 97932690T ES 97932690 T ES97932690 T ES 97932690T ES 2256893 T3 ES2256893 T3 ES 2256893T3
Authority
ES
Spain
Prior art keywords
cells
oligonucleotide
antisense oligonucleotide
antisense
neoplastic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES97932690T
Other languages
English (en)
Spanish (es)
Inventor
Jim A. Wright
Aiping H. Young
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genesense Technologies Inc
Original Assignee
Genesense Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genesense Technologies Inc filed Critical Genesense Technologies Inc
Application granted granted Critical
Publication of ES2256893T3 publication Critical patent/ES2256893T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0093—Oxidoreductases (1.) acting on CH or CH2 groups (1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C12N2310/111—Antisense spanning the whole gene, or a large part of it
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES97932690T 1996-08-02 1997-08-01 Secuencias antisentido antitumorales dirigidas contra componentes r1 y r2 de la reductasa ribonucleica. Expired - Lifetime ES2256893T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2304096P 1996-08-02 1996-08-02
US23040P 1996-08-02
US3995997P 1997-03-07 1997-03-07
US39959P 1997-03-07

Publications (1)

Publication Number Publication Date
ES2256893T3 true ES2256893T3 (es) 2006-07-16

Family

ID=26696655

Family Applications (1)

Application Number Title Priority Date Filing Date
ES97932690T Expired - Lifetime ES2256893T3 (es) 1996-08-02 1997-08-01 Secuencias antisentido antitumorales dirigidas contra componentes r1 y r2 de la reductasa ribonucleica.

Country Status (12)

Country Link
US (1) US5998383A (enExample)
EP (1) EP0917569B1 (enExample)
JP (1) JP4301576B2 (enExample)
CN (1) CN1189562C (enExample)
AT (1) ATE309345T1 (enExample)
AU (1) AU738592C (enExample)
CA (1) CA2262776C (enExample)
DE (1) DE69734589T2 (enExample)
ES (1) ES2256893T3 (enExample)
IL (2) IL128124A0 (enExample)
NZ (1) NZ333802A (enExample)
WO (1) WO1998005769A2 (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1223831A (en) 1982-06-23 1987-07-07 Dean Engelhardt Modified nucleotides, methods of preparing and utilizing and compositions containing the same
US7223849B1 (en) * 1996-07-01 2007-05-29 Genesense Technologies Inc. Oligonucleotides from the untranslated regions of housekeeping genes and methods of using same to modulate cell growth
US6593305B1 (en) 1996-08-02 2003-07-15 Genesense Technologies Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
DE69823813T2 (de) 1997-03-19 2005-06-30 Genesense Technologies, Inc., Toronto Malignitätsunterdrückung unter verwendung von ribonukleotidreduktase r1
US6835395B1 (en) 1997-05-14 2004-12-28 The University Of British Columbia Composition containing small multilamellar oligodeoxynucleotide-containing lipid vesicles
EP1584681A3 (en) * 1997-07-10 2005-11-09 GeneSense Technologies Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
US6610539B1 (en) * 1997-07-10 2003-08-26 Genesense Technologies, Inc. Antisense oligonucleotide sequences as inhibitors of microorganisms
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
CN101818145A (zh) * 1998-03-20 2010-09-01 联邦科学和工业研究组织 控制基因表达
AUPP249298A0 (en) 1998-03-20 1998-04-23 Ag-Gene Australia Limited Synthetic genes and genetic constructs comprising same I
AU776150B2 (en) * 1999-01-28 2004-08-26 Medical College Of Georgia Research Institute, Inc. Composition and method for (in vivo) and (in vitro) attenuation of gene expression using double stranded RNA
US6121000A (en) * 1999-02-11 2000-09-19 Genesense Technologies, Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
US20040138168A1 (en) * 1999-04-21 2004-07-15 Wyeth Methods and compositions for inhibiting the function of polynucleotide sequences
US6642033B1 (en) 1999-07-20 2003-11-04 V.I. Technologies, Inc. Nucleic acids for detecting parvovirus and methods of using same
US6423885B1 (en) 1999-08-13 2002-07-23 Commonwealth Scientific And Industrial Research Organization (Csiro) Methods for obtaining modified phenotypes in plant cells
CN1301816A (zh) * 1999-12-27 2001-07-04 上海博德基因开发有限公司 一种新的多肽——核苷酸还原酶10和编码这种多肽的多核苷酸
CN1426466A (zh) * 2000-03-17 2003-06-25 贝尼泰克澳大利亚有限公司 遗传沉默
US20020132257A1 (en) * 2001-01-31 2002-09-19 Tony Giordano Use of post-transcriptional gene silencing for identifying nucleic acid sequences that modulate the function of a cell
DE10131148A1 (de) * 2001-06-28 2003-01-16 I P L Internat Pharmaceutics L Xenogene Oligo- oder/und Polyribonukleotide als Mittel zur Behandlung von malignen Tumoren
JP2006518344A (ja) * 2003-02-10 2006-08-10 ジェネセンス テクノロジーズ インク リボヌクレオチド還元酵素ｒ２を指向するアンチセンスオリゴヌクレオチドおよび癌の治療におけるこれらの使用
AU2003225410A1 (en) * 2003-03-21 2004-10-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
CA2526393A1 (en) * 2003-05-21 2004-12-02 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r1 and uses thereof in the treatment of cancer
WO2004106518A1 (en) * 2003-05-31 2004-12-09 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in the treatment of cancer
BRPI0415771A (pt) 2003-10-23 2006-12-26 Illumigen Biosciences Inc detecção de mutações em um gene associado à resistência a infecção viral, oas1
EP1715896A4 (en) * 2004-01-12 2009-01-07 Lorus Therapeutics Inc ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST RIBONUCLEOTIDE REDUCTASE R2 AND USE THEREOF IN POLYTHERAPIES FOR THE TREATMENT OF CANCER
US8029815B2 (en) * 2004-04-28 2011-10-04 Elford Howard L Methods for treating or preventing restenosis and other vascular proliferative disorders
CA2566519C (en) * 2004-05-14 2020-04-21 Rosetta Genomics Ltd. Micrornas and uses thereof
US7968762B2 (en) * 2004-07-13 2011-06-28 Van Andel Research Institute Immune-compromised transgenic mice expressing human hepatocyte growth factor (hHGF)
WO2006017932A1 (en) * 2004-08-18 2006-02-23 Genesense Technologies Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
US20060185027A1 (en) * 2004-12-23 2006-08-17 David Bartel Systems and methods for identifying miRNA targets and for altering miRNA and target expression
PL1866414T3 (pl) * 2005-03-31 2012-10-31 Calando Pharmaceuticals Inc Inhibitory podjednostki 2 reduktazy rybonukleotydowej i ich zastosowania
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
US9526707B2 (en) * 2007-08-13 2016-12-27 Howard L. Elford Methods for treating or preventing neuroinflammation or autoimmune diseases
US20100204305A1 (en) * 2007-12-11 2010-08-12 Lorus Therapeutics Inc. Small interfering rna molecules against ribonucleotide reductase and uses thereof
JP2011506560A (ja) 2007-12-20 2011-03-03 ノバルティス アーゲー Ｐｉ３キナーゼ阻害剤として用いられるチアゾール誘導体
WO2010027279A2 (en) * 2008-09-04 2010-03-11 Genesis Research And Development Corporation Limited Compositions and methods for the treatment and prevention of neoplastic disorders
EP2350264A4 (en) 2008-11-06 2012-08-29 Univ Johns Hopkins TREATMENT OF CHRONIC INFLAMMATION OF THE RESPIRATORY TRACT
US8293753B2 (en) 2009-07-02 2012-10-23 Novartis Ag Substituted 2-carboxamide cycloamino ureas
AR082418A1 (es) 2010-08-02 2012-12-05 Novartis Ag Formas cristalinas de 1-(4-metil-5-[2-(2,2,2-trifluoro-1,1-dimetil-etil)-piridin-4-il]-tiazol-2-il)-amida de 2-amida del acido (s)-pirrolidin-1,2-dicarboxilico
EP3434772A3 (en) * 2010-10-18 2019-03-20 Arrowhead Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of rrm2 genes
WO2012104776A1 (en) 2011-01-31 2012-08-09 Novartis Ag Novel heterocyclic derivatives
SG11201401716XA (en) 2011-10-28 2014-05-29 Novartis Ag Novel purine derivatives and their use in the treatment of disease
CN104349779A (zh) 2012-05-16 2015-02-11 诺华股份有限公司 Pi-3激酶抑制剂的剂量方案
DK3076969T3 (da) 2013-12-06 2021-11-22 Novartis Ag Doseringsregime for en alfa-isoform-selektiv phosphatidylinositol-3-kinase-hæmmer
CN108472289A (zh) 2015-11-02 2018-08-31 诺华股份有限公司 磷脂酰肌醇3-激酶抑制剂的给药方案
WO2018060833A1 (en) 2016-09-27 2018-04-05 Novartis Ag Dosage regimen for alpha-isoform selective phosphatidylinositol 3-kinase inhibitor alpelisib
AU2021244786A1 (en) 2020-03-25 2022-11-03 Risen (Suzhou) Pharma Tech Co., Ltd. Stable heavy isotopes in amide functional groups and uses thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
EP0690869A1 (en) * 1993-03-23 1996-01-10 The Board Of Trustees Of The Leland Stanford Junior University Cellular regulation with riboregulators

Also Published As

Publication number Publication date
US5998383A (en) 1999-12-07
WO1998005769A2 (en) 1998-02-12
AU738592C (en) 2002-07-25
DE69734589T2 (de) 2006-08-10
JP4301576B2 (ja) 2009-07-22
EP0917569A2 (en) 1999-05-26
IL128124A (en) 2006-12-31
AU738592B2 (en) 2001-09-20
CN1231694A (zh) 1999-10-13
NZ333802A (en) 2001-09-28
JP2000517167A (ja) 2000-12-26
CN1189562C (zh) 2005-02-16
AU3617597A (en) 1998-02-25
DE69734589D1 (de) 2005-12-15
IL128124A0 (en) 1999-11-30
EP0917569B1 (en) 2005-11-09
ATE309345T1 (de) 2005-11-15
CA2262776A1 (en) 1998-02-12
WO1998005769A3 (en) 1998-06-25
CA2262776C (en) 2005-03-08

Similar Documents

Publication Publication Date Title
EP0917569B1 (en) Antitumor antisense sequences directed against r1 and r2 components of ribonucleotide reductase
JP4062365B2 (ja) 短い外部ガイド配列
EP0748383B1 (en) Targeted cleavage of rna using ribonuclease p targeting and cleavage sequences
JP4424857B2 (ja) リボヌクレオチドレダクターゼのｒ１及びｒ２成分に対する抗腫瘍アンチセンス配列
Halatsch et al. Marked inhibition of glioblastoma target cell tumorigenicity in vitro by retrovirus-mediated transfer of a hairpin ribozyme against deletion-mutant epidermal growth factor messenger RNA
ES2326118T3 (es) Regulacion de la expresion del gen bcl-2.
CA2259123C (en) Oligonucleotides from the untranslated regions of ribonucleotide reductase and their use to modulate cell growth
US5635385A (en) Multi-unit ribozyme inhibition of oncogene gene expression
ES2228119T3 (es) Modulacion de la expresion de la adn-metil-tranferasa mediante terapia de combinacion.
ES2260376T3 (es) Ribozimas dirigidas contra una secuencia tat del vih.
JP2008545011A (ja) Ｈ１９をダウンレギュレートする核酸薬剤、及びそれを使用する方法
JPH10512559A (ja) 過増殖症の併用療法
Folini et al. Targeting telomerase by antisense-based approaches: perspectives for new anti-cancer therapies
KR20010040448A (ko) 티오레독신 또는 티오레독신 환원효소의 유전자와상보적인 올리고뉴클레오 타이드 서열 및 이들을 사용하는세포성장 조절 방법
WO2008106781A1 (en) Treatment of squamous cell carcinoma with hsp27 antisense oligonucleotides and radiotherapy
US7405205B2 (en) Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
ES2288318T3 (es) Uso de dna-pk.
Kiely Recent advances in antisense technology
Prins et al. Antisense of oligonucleotides and the inhibition of oncogene expression
Sang Cho-Chung Overview: Oncologic, Endocrine & Metabolic Antisense oligonucleotides for the treatment of cancer
AU9732101A (en) Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
Kijima et al. Cancer Gene Therapy
Tan et al. THERAPEUTIC APPLICATIONS OF ANTISENSE NUCLEIC ACIDS
Hawley et al. Suppression of ras Oncogene Expression Using Sequence Specific Oligodeoxynucleotides